Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

Official Title

An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT)

Keywords

Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Cancer vaccine, RNA vaccine, HNSCC, BNT113, Pembrolizumab, HPV16, Metastatic, Unresectable, Recurrent, Head and neck, mRNA vaccine, HPV-positive, Head and neck cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Papilloma, Recurrence

Eligibility

Locations

  • UCLA Cancer Care accepting new patients
    Los Angeles California 90095 United States
  • California Research Institute accepting new patients
    Los Angeles California 90027 United States
  • Stanford Cancer Institute completed
    Palo Alto California 94304 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
BioNTech SE
ID
NCT04534205
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 285 study participants
Last Updated